RELATIVITY-047's 5-year survival data and LAG-3-high CD8+ T cell biomarker findings signal a shift in how immuno-oncology ...

Tarlatamab plus durvalumab cuts death risk 58% in first-line small cell lung cancer, extending median overall survival to ...

NHWD-870 HCl achieves 45% response rate in thoracic NUT carcinoma, nearly doubling the overall cohort's 30% rate in advanced ...

Lilly's sofetabart mipitecan achieves 79% response rate in platinum-sensitive ovarian cancer patients, including those with prior PARP inhibitor exposure.

ASP-1929 + Pembrolizumab achieved 28.2-month median OS in recurrent/metastatic HNSCC, with 35% alive at four years in Phase ...

Tango Therapeutics updates vopimetostat Phase 1/2 Trial results in combination with RAS(ON) inhibitors. Full data available in SEC filing.

Medpace wins the SCRS Eagle Award for CRO for the second consecutive year, based on ratings from nearly 2,000 global research sites.

WCG's Activation Intelligence targets clinical trial rework by catching document conflicts before activation, saving sites ...

Upacicalcet meets primary endpoints in Phase 3 trials for secondary hyperparathyroidism, with 42–44% of patients achieving 30% PTH reduction versus 17% on place ...

Clinical Solutions appoints three C-suite executives to lead product, finance, and talent functions amid strong first-half ...

Sefaxersen achieves 43% proteinuria reduction in Phase 3 IgA Nephropathy Study, targeting disease mechanisms beyond standard care in kidney disease treatment.

Perspective Therapeutics' lead-212 radiopharmaceutical shows responses in neuroendocrine tumor trial, with interim Phase 1/2a data presented at European nuclear ...